Why the study?
Ischemic cardiomyopathy poses significant clinical challenges due to complex pathophysiology and poor prognosis, while recent advances in medical, device, and revascularization therapies offer new potential to improve outcomes.
A personalized treatment approach integrating medical, revascularization, and device therapies is essential for managing the complex pathophysiology of ischemic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May inform ischemic cardiomyopathy care; leaves open prospective validation of integrated strategies.
Ischemic heart disease (IHD) is the leading global cause of death, affecting millions and leading to significant morbidity and mortality. Ischemic cardiomyopathy (ICM), a manifestation of IHD, results in severe left ventricular dysfunction due to coronary artery disease and poses a significant challenge due to the complex pathophysiology, variable clinical presentation, and overall poor prognosis. Recent advances in medical therapy, device interventions, and revascularization techniques offer newfound hope in improving ICM patient outcomes. This article reviews the state-of-the-art management approaches for ICM, emphasizing the importance of personalized treatment plans that integrate the various contemporary therapies to address the multiple mechanisms of disease development and progression. A meticulously tailored treatment approach for each individual patient offers the hope of prolonged survival through the synergy of therapies designed to address the different and complex mechanisms that contribute to their disease process.
No takes yet. Share an insight, caveat, or question.
Isath et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: